UroGen Pharma Ltd. SEC filings URGN
UroGen Pharma Ltd. has 583 filings in SEC EDGAR's recent list, going back to Mar 4, 2016. Its latest annual report, Form ARS, was filed on May 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| UPLOAD | Letter from the SEC | Dec 5, 2023 | — |
| CORRESP | Letter to the SEC | Nov 27, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2023 | — |
| EFFECT | Filing | Sep 15, 2023 | — |
| CORRESP | Letter to the SEC | Sep 13, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 12, 2023 | — |
| D | Filing | Aug 14, 2023 | — |
| EFFECT | Filing | Nov 29, 2022 | — |
| CORRESP | Letter to the SEC | Nov 23, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2022 | — |
| EFFECT | Filing | Jan 2, 2020 | — |
| CORRESP | Letter to the SEC | Dec 30, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 27, 2019 | — |
| UPLOAD | Letter from the SEC | May 30, 2019 | — |
| CORRESP | Letter to the SEC | May 29, 2019 | — |
| UPLOAD | Letter from the SEC | May 17, 2019 | — |
| CORRESP | Letter to the SEC | May 14, 2019 | — |
| UPLOAD | Letter from the SEC | May 8, 2019 | — |
| EFFECT | Filing | Oct 26, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2018 | — |
| CORRESP | Letter to the SEC | Oct 24, 2018 | — |
| EFFECT | Filing | Jan 18, 2018 | — |
| DRS | Filing | Dec 22, 2017 | — |
| CT ORDER | Filing | May 4, 2017 | — |
| EFFECT | Filing | May 3, 2017 | — |
| CERTNAS | Auto-generated paper document | May 2, 2017 | — |
| CORRESP | Letter to the SEC | May 1, 2017 | — |
| CORRESP | Letter to the SEC | May 1, 2017 | — |
| 8-A12B | Form 8-a12b | May 1, 2017 | — |
| CORRESP | Letter to the SEC | Apr 19, 2017 | — |
| DRSLTR | Filing | Mar 31, 2017 | — |
| DRS/A | Filing | Mar 31, 2017 | — |
| UPLOAD | Letter from the SEC | Mar 16, 2017 | — |
| DRS/A | Filing | Mar 9, 2017 | — |
| DRSLTR | Filing | Mar 8, 2017 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2017 | — |
| DRSLTR | Filing | Dec 28, 2016 | — |
| DRS/A | Filing | Dec 28, 2016 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2016 | — |
| DRS/A | Filing | Dec 7, 2016 | — |
| DRS/A | Filing | Jun 7, 2016 | — |
| DRSLTR | Filing | May 17, 2016 | — |
| DRS/A | Filing | May 17, 2016 | — |
| UPLOAD | Letter from the SEC | May 9, 2016 | — |
| DRSLTR | Filing | Apr 20, 2016 | — |
| DRS/A | Filing | Apr 20, 2016 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2016 | — |
| DRS | Filing | Mar 4, 2016 | — |
Showing 48 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- URGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Ra'Anana, Israel
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1668243
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.